Cargando…

Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials

BACKGROUND: This report evaluated the cardiovascular safety of the amylin analog pramlintide—an existing diabetes injectable treatment—by comparing relevant cardiovascular adverse events (AEs) reported in previous phase 3 and 4 clinical trials among patients receiving pramlintide and those receiving...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrmann, Kathrin, Zhou, Ming, Wang, Andrew, de Bruin, Tjerk W. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471856/ https://www.ncbi.nlm.nih.gov/pubmed/28702246 http://dx.doi.org/10.1186/s40842-016-0030-z

Ejemplares similares

Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials
por: Herrmann, Kathrin, et al.
Publicado: (2016)

Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes
por: Riddle, M. C., et al.
Publicado: (2015)

Pramlintide in the Management of Insulin-Using Patients with Type 2 and Type 1 Diabetes
por: Pullman, John, et al.
Publicado: (2006)

Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
por: Ryan, Gina, et al.
Publicado: (2009)

Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis
por: Qiao, Yong-Chao, et al.
Publicado: (2017)

Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
por: Riddle, Matthew, et al.
Publicado: (2009)

Ultra‐Fast Insulin–Pramlintide Co‐Formulation for Improved Glucose Management in Diabetic Rats
por: Maikawa, Caitlin L., et al.
Publicado: (2021)

Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Zn(II) binding to pramlintide results in a structural kink, fibril formation and antifungal activity
por: Dudek, Dorota, et al.
Publicado: (2022)

Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes
por: Weinzimer, Stuart A., et al.
Publicado: (2012)

The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro
por: Safaeian, Leila, et al.
Publicado: (2020)

Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming
por: Yang, Yuanzheng, et al.
Publicado: (2022)

Study of forced degradation behavior of pramlintide acetate by HPLC and LC–MS
por: Yuan, Yu, et al.
Publicado: (2017)

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
por: Iqbal, Nayyar, et al.
Publicado: (2014)

Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts
por: Mousa, Youssef M., et al.
Publicado: (2020)

SAT-LB028 Efficacy and Safety of Pramlintide as an Adjunct to Insulin U500 Therapy in Veterans with Severe Insulin Resistance
por: Oprea, Mihaela, et al.
Publicado: (2019)

A co-formulation of supramolecularly stabilized insulin and pramlintide enhances meal-time glucagon suppression in diabetic pigs
por: Maikawa, Caitlin L., et al.
Publicado: (2020)

Contraction of human brain vascular pericytes in response to islet amyloid polypeptide is reversed by pramlintide
por: Nuñez-Diaz, Cristina, et al.
Publicado: (2023)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013)

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
por: Smith, Steve R., et al.
Publicado: (2008)

Author Correction: Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts
por: Mousa, Youssef M., et al.
Publicado: (2020)

Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide
por: Tyagi, Puneet, et al.
Publicado: (2022)

Effects of interacting networks of cardiovascular risk genes on the risk of type 2 diabetes mellitus (the CODAM study)
por: van Greevenbroek, Marleen MJ, et al.
Publicado: (2008)

A Phase 2 Evaluation of a Novel Co-Formulation of Pramlintide and Regular Insulin to Improve Postprandial Glycemic Control in Adults with Type 1 Diabetes (T1D)
por: Edelman, Steven Victor, et al.
Publicado: (2021)

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
por: Rosenstock, Julio, et al.
Publicado: (2015)

Pramlintide regulation of extracellular matrix (ECM) and apoptosis through mitochondrial-dependent pathways in human nucleus pulposus cells
por: Wu, Xinghuo, et al.
Publicado: (2017)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
por: REICH, Kristian, et al.
Publicado: (2022)

Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
por: Hoogwerf, Byron J, et al.
Publicado: (2008)

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
por: Williams-Herman, Debora, et al.
Publicado: (2008)

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Kinduryte Schorling, Ona, et al.
Publicado: (2020)

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
por: Cefalu, William T., et al.
Publicado: (2015)

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
por: Ginsberg, Henry N., et al.
Publicado: (2018)

Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data
por: Davies, Michael J., et al.
Publicado: (2017)

Walkability and its association with prevalent and incident diabetes among adults in different regions of Germany: results of pooled data from five German cohorts
por: Kartschmit, Nadja, et al.
Publicado: (2020)

Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials
por: Choy, Ernest H. S., et al.
Publicado: (2009)

Age at diagnosis of type 2 diabetes and cardiovascular risk factor profile: A pooled analysis
por: Barker, Mary M, et al.
Publicado: (2022)

Pramlintide: An Amylin Analogue Protects Endothelial Cells against Oxidative Stress through Regulating Oxidative Markers and NF-κb Expression
por: Safaeian, Leila, et al.
Publicado: (2022)

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials
por: von Eynatten, Maximilian, et al.
Publicado: (2013)

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
por: Engel, Samuel S., et al.
Publicado: (2013)

Development and validation of a new robust RP-HPLC method for simultaneous quantitation of insulin and pramlintide in non-invasive and smart glucose-responsive microparticles
por: Emami, Jaber, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g072q1u1i56lmr95t4lsfl12ci